Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

NCT05484622 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Astrocytoma
Oligodendroglioma

Interventions

DRUG: Vorasidenib
DRUG: Pembrolizumab

Sponsor

Institut de Recherches Internationales Servier

Collaborators

[object Object]